Skip to main content
TipRanks
Go Ultimate75% OFF

Isofol Medical AB (5IU) AI Stock Analysis

1 Followers
DE:5IU

Isofol Medical AB

(Frankfurt:5IU)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Focused oncology pipelineA focused oncology candidate gives Isofol a defined development strategy rather than a broad, unfocused research portfolio. If clinical and regulatory objectives are achieved, arfolitixorin could support a scalable product opportunity within established chemotherapy treatment pathways.
Negative Factors
No meaningful commercial revenueThe absence of meaningful revenue confirms that Isofol has not yet established a commercial earnings base. Until a product is approved and adopted, operating performance will remain tied to development progress rather than recurring customer demand or product sales.

Isofol Medical AB (5IU) vs. iShares MSCI Germany ETF (EWG)

-50%0%50%100%150%200%DE:5IU+66.67%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 30.52M
Dividend Yield
―
Average Volume (3M)
23.33K
Price to Earnings (P/E)
-5.6
Beta (1Y)
0.21
Revenue Growth
―
EPS Growth
33.20%
Country
Germany
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Isofol Medical AB Business Overview & Revenue Model

Company Description

Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is pre...

Isofol Medical AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:5IU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA61NeutralSEK 386.26M2.0163.09%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:IMMUSE:IMMU48NeutralSEK 253.42M-2.23-19.14%――13.06%
SE:ELICSE:ELIC47NeutralSEK 166.84M-7.07-56.09%――14.10%
SE:ONCOSE:ONCO44NeutralSEK 763.93M-2.81――65.37%43.28%
SE:BINVSE:BINV43NeutralSEK 180.96M-0.37-128.54%―-83.67%-50.29%

* Healthcare Sector Average

Performance Comparison

0%100%DE:5IUSE:BINVSE:ONCOSE:ELICSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:5IU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:5IUIsofol Medical AB0.080.0366.67%
SE:BINVBioInvent International AB2.75-26.20-90.50%
SE:ONCOOncopeptides AB1.77-3.04-63.20%
SE:ELICElicera Therapeutics AB2.50-2.78-52.66%
SE:IMMUImmunicum AB4.00-1.54-27.89%
SE:CANTACantargia AB1.37-2.05-60.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.